Brokerages expect OptiNose Inc (NASDAQ:OPTN) to report earnings per share of ($0.84) for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for OptiNose’s earnings. The highest EPS estimate is ($0.79) and the lowest is ($0.88). OptiNose reported earnings of ($0.64) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 31.3%. The business is expected to report its next quarterly earnings results on Tuesday, March 12th.
According to Zacks, analysts expect that OptiNose will report full-year earnings of ($2.93) per share for the current year, with EPS estimates ranging from ($3.04) to ($2.76). For the next fiscal year, analysts expect that the firm will report earnings of ($2.75) per share, with EPS estimates ranging from ($3.19) to ($2.29). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that follow OptiNose.
OptiNose (NASDAQ:OPTN) last posted its quarterly earnings results on Tuesday, November 13th. The company reported ($0.61) EPS for the quarter, beating the consensus estimate of ($0.72) by $0.11. The business had revenue of $1.90 million during the quarter, compared to analysts’ expectations of $1.57 million.
Several equities research analysts have commented on OPTN shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of OptiNose in a report on Wednesday, August 15th. Zacks Investment Research lowered shares of OptiNose from a “buy” rating to a “hold” rating in a report on Wednesday, August 15th. Piper Jaffray Companies set a $30.00 target price on shares of OptiNose and gave the stock a “buy” rating in a research note on Tuesday, August 14th. Finally, BMO Capital Markets lowered their target price on shares of OptiNose from $30.00 to $28.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 15th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $28.75.
Several hedge funds have recently bought and sold shares of OPTN. BlackRock Inc. boosted its stake in shares of OptiNose by 336.0% during the 2nd quarter. BlackRock Inc. now owns 997,257 shares of the company’s stock worth $27,903,000 after acquiring an additional 768,521 shares in the last quarter. Thrivent Financial for Lutherans boosted its stake in shares of OptiNose by 120.7% during the 3rd quarter. Thrivent Financial for Lutherans now owns 1,282,231 shares of the company’s stock worth $15,939,000 after acquiring an additional 701,352 shares in the last quarter. Foresite Capital Management IV LLC boosted its stake in shares of OptiNose by 57.1% during the 3rd quarter. Foresite Capital Management IV LLC now owns 1,458,545 shares of the company’s stock worth $18,130,000 after acquiring an additional 530,000 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of OptiNose by 39.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,874,231 shares of the company’s stock worth $23,297,000 after acquiring an additional 526,501 shares in the last quarter. Finally, FMR LLC boosted its stake in shares of OptiNose by 7.7% during the 2nd quarter. FMR LLC now owns 6,117,208 shares of the company’s stock worth $171,160,000 after acquiring an additional 437,747 shares in the last quarter. 50.30% of the stock is currently owned by institutional investors and hedge funds.
NASDAQ:OPTN opened at $8.08 on Wednesday. OptiNose has a one year low of $7.33 and a one year high of $30.00. The company has a debt-to-equity ratio of 0.51, a quick ratio of 10.13 and a current ratio of 10.44.
OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.
Further Reading: Penny Stocks, What You Need To Know
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.